Company / R&D Expense
Maze Therapeutics, Inc. R&D Expense History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$108.4M
FY2025
5-year range
$108.4M / $108.4M
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#137 of 210
Health Care
What the data says
At $108M, Maze Therapeutics, Inc.'s r&d expense ranks #137 of 210 in the Health Care sector.
Based on SEC 10-K filings.
$108M in FY2025.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#137 of 210 in Health CareTop 65% of 210This company $108.4M Sector average $644.1M
▼
-83.2% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $108.4M | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026